Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early diabetes - RELEASE

niversitair Medisch Centrum Groningen0 个研究点目标入组 45 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•- Men and women, age 30 to 70 years, AND
•- Treatment naïve type 2 diabetes, as defined as the presence of one of the following (American Diabetes Association definition:
•- Fasting plasma glucose >= 7.0 mmol/l, OR
•- Random plasma glucose >= 11.1 mmol/l, OR
•- HbA1c >=6,5%
•- written informed consent

•- Current or previous use of glycemic control medications
•- Type 1 diabetes
•- Gestational diabetes mellitus
•- Other specific types of diabetes due to other causes
•- Uncontrolled hypertension, defined as systolic blood pressure >160 or a diastolic blood pressure >100 mmHg at screening visit
•- Severe dyslipidemia indicating primary dyslipidemia, defined as total cholesterol >8 mmol/l, tryglicerides >10 mmol/l of high density lipoprotein cholesterol <0.6 mmol/l
•- Current use of weight loss medication or previous weight loss surgery
•- History of severe gastrointestinal disease
•- Clinical contraindications to DPP4-inhibitors
•- Previous cardiovascular disease, defined as stable coronary artery disease or acute coronary syndrome, stroke or transient ischemic attack, peripheral artery disease
•- Symptomatic heart failure, New York Heart Association (NYHA) class II-IV
•- Women who are currently pregnant,planning to become pregnant,breastfeeding women, or women with child bearing potential not using appropriate contraceptive measures
•- Clinically significant liver disease or hepatic function greater than 3 times upper limit of normal
•- Known impaired renal function or eGFR <30 ml/min/1.73m2
•- Patients who are mentally incompetent and cannot sign a Patient Informed Consent
•- Current active malignancy or in the previous 6 months
•- Documented HIV infection
•- Use of rifampicin
•- Known or suspected allergy to 18F-FDG or its components

发起方